Skip to main content
SpringerLink
Log in
Book cover

Neurodegenerative Diseases: Integrative PPPM Approach as the Medicine of the Future pp 69–92Cite as

Tau Pathology: A Selected View on the Current Status

  • Chapter
  • First Online:

  • 946 Accesses

Part of the book series: Advances in Predictive, Preventive and Personalised Medicine ((APPPM,volume 2))

Abstract

Tau (tubulin associated unit) is a microtubule regulatory protein forming pathological aggregates in multiple neurodegenerative disease termed tauopathies. Microtubules are key cytoskeletal elements found in all eukaryotic cells, comprising the mitotic spindle in dividing cells and the skeleton and transport system of the nerve cell. The polymerized microtubule shaft (a hollow cylinder of ∼250 nm) is composed of the heterodimer protein, tubulin. Microtubules are decorated with multiple microtubule associated regulatory proteins (MAPs). Tau (MAPT), among the first microtubule associated proteins to be identified, was implicated in microtubule initiation as well as assembly, with increased expression in neurons and specific association with axonal microtubules. Alzheimer’s disease (AD) is the most prevalent tauopathy, exhibiting tau-neurofibrillary tangles associated with cognitive dysfunction. AD is also characterized by β-amyloid plaques. An abundance of tau inclusions, in the absence of β-amyloid deposits, can be found in Pick’s disease, progressive supranuclear palsy (PSP), corticobasal degeneration (CBD) and other diseases, collectively described as tauopathies. The increase in tau pathology in AD correlates with the associated cognitive decline. This book chapter is an update on several recent reviews. It is not a comprehensive review of the literature, but rather an updating point of view.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Gozes I (2010) Tau pathology and future therapeutics. Curr Alzheimer Res 7:685–696

    Article  PubMed  CAS  Google Scholar 

  2. Gozes I (2011) Microtubules, schizophrenia and cognitive behavior: preclinical development of davunetide (NAP) as a peptide-drug candidate. Peptides 32:428–431

    Article  PubMed  CAS  Google Scholar 

  3. Gozes I (2011) NAP (davunetide) provides functional and structural neuroprotection. Curr Pharm Des 17:1040–1044

    Article  PubMed  CAS  Google Scholar 

  4. Gozes I (2011) Microtubules (tau) as an emerging therapeutic target: NAP (davunetide). Curr Pharm Des 17:3413–3417

    Article  PubMed  CAS  Google Scholar 

  5. Gold M, Lorenzl S, Stewart AJ, Morimoto BH, Williams DR, Gozes I (2012) Critical appraisal of the role of davunetide in the treatment of progressive supranuclear palsy. Neuropsychiatr Dis Treat 8:85–93

    PubMed  CAS  Google Scholar 

  6. Goedert M, Crowther RA, Spillantini MG (1998) Tau mutations cause frontotemporal dementias. Neuron 21:955–958

    Article  PubMed  CAS  Google Scholar 

  7. Gozes I, Littauer UZ (1978) Tubulin microheterogeneity increases with rat brain maturation. Nature 276:411–413

    Article  PubMed  CAS  Google Scholar 

  8. Gozes I, Sweadner KJ (1981) Multiple tubulin forms are expressed by a single neurone. Nature 294:477–480

    Article  PubMed  CAS  Google Scholar 

  9. Gozes I, Saya D, Littauer UZ (1979) Tubulin microheterogeneity in neuroblastoma and glioma cell lines differs from that of the brain. Brain Res 171:171–175

    Article  PubMed  CAS  Google Scholar 

  10. Gao J, Dennis JE, Muzic RF, Lundberg M, Caplan AI (2001) The dynamic in vivo distribution of bone marrow-derived mesenchymal stem cells after infusion. Cells Tissues Organs 169:12–20

    Article  PubMed  CAS  Google Scholar 

  11. Cleveland DW, Hwo SY, Kirschner MW (1977) Purification of tau, a microtubule-associated protein that induces assembly of microtubules from purified tubulin. J Mol Biol 116:207–225

    Article  PubMed  CAS  Google Scholar 

  12. Witman GB, Cleveland DW, Weingarten MD, Kirschner MW (1976) Tubulin requires tau for growth onto microtubule initiating sites. Proc Natl Acad Sci U S A 73:4070–4074

    Article  PubMed  CAS  Google Scholar 

  13. Bernhardt R, Matus A (1984) Light and electron microscopic studies of the distribution of microtubule-associated protein 2 in rat brain: a difference between dendritic and axonal cytoskeletons. J Comp Neurol 226:203–221

    Article  PubMed  CAS  Google Scholar 

  14. Weingarten MD, Lockwood AH, Hwo SY, Kirschner MW (1975) A protein factor essential for microtubule assembly. Proc Natl Acad Sci U S A 72:1858–1862

    Article  PubMed  CAS  Google Scholar 

  15. Cleveland DW, Hwo SY, Kirschner MW (1977) Physical and chemical properties of purified tau factor and the role of tau in microtubule assembly. J Mol Biol 116:227–247

    Article  PubMed  CAS  Google Scholar 

  16. Drubin DG, Caput D, Kirschner MW (1984) Studies on the expression of the microtubule-associated protein, tau, during mouse brain development, with newly isolated complementary DNA probes. J Cell Biol 98:1090–1097

    Article  PubMed  CAS  Google Scholar 

  17. Ebneth A, Godemann R, Stamer K, Illenberger S, Trinczek B, Mandelkow E (1998) Overexpression of tau protein inhibits kinesin-dependent trafficking of vesicles, mitochondria, and endoplasmic reticulum: implications for Alzheimer’s disease. J Cell Biol 143:777–794

    Article  PubMed  CAS  Google Scholar 

  18. Stamer K, Vogel R, Thies E, Mandelkow E, Mandelkow EM (2002) Tau blocks traffic of organelles, neurofilaments, and APP vesicles in neurons and enhances oxidative stress. J Cell Biol 156:1051–1063

    Article  PubMed  CAS  Google Scholar 

  19. Gozes I (1982) Tubulin in the nervous system. Neurochem Int 4:101–120

    Article  PubMed  CAS  Google Scholar 

  20. Goedert M, Spillantini MG, Jakes R, Rutherford D, Crowther RA (1989) Multiple isoforms of human microtubule-associated protein tau: sequences and localization in neurofibrillary tangles of Alzheimer’s disease. Neuron 3:519–526

    Article  PubMed  CAS  Google Scholar 

  21. Himmler A, Drechsel D, Kirschner MW, Martin DW Jr (1989) Tau consists of a set of proteins with repeated C-terminal microtubule-binding domains and variable N-terminal domains. Mol Cell Biol 9:1381–1388

    PubMed  CAS  Google Scholar 

  22. Stoothoff W, Jones PB, Spires-Jones TL, Joyner D, Chhabra E, Bercury K, Fan Z, Xie H, Bacskai B, Edd J, Irimia D, Hyman BT (2009) Differential effect of three-repeat and four-repeat tau on mitochondrial axonal transport. J Neurochem 111:417–427

    Article  PubMed  CAS  Google Scholar 

  23. Shemesh OA, Erez H, Ginzburg I, Spira ME (2008) Tau-induced traffic jams reflect organelles accumulation at points of microtubule polar mismatching. Traffic 9:458–471

    Article  PubMed  CAS  Google Scholar 

  24. Witte H, Neukirchen D, Bradke F (2008) Microtubule stabilization specifies initial neuronal polarization. J Cell Biol 180:619–632

    Article  PubMed  CAS  Google Scholar 

  25. Eickholt BJ, Walsh FS, Doherty P (2002) An inactive pool of GSK-3 at the leading edge of growth cones is implicated in Semaphorin 3A signaling. J Cell Biol 157:211–217

    Article  PubMed  CAS  Google Scholar 

  26. Hoover BR, Reed MN, Su J, Penrod RD, Kotilinek LA, Grant MK, Pitstick R, Carlson GA, Lanier LM, Yuan LL, Ashe KH, Liao D (2010) Tau mislocalization to dendritic spines mediates synaptic dysfunction independently of neurodegeneration. Neuron 68:1067–1081

    Article  PubMed  CAS  Google Scholar 

  27. Lee S, Kim W, Li Z, Hall GF (2012) Accumulation of vesicle-associated human tau in distal dendrites drives degeneration and tau secretion in an in situ cellular tauopathy model. Int J Alzheimers Dis 2012:172837

    PubMed  Google Scholar 

  28. Dickstein DL, Brautigam H, Stockton SD Jr, Schmeidler J, Hof PR (2010) Changes in dendritic complexity and spine morphology in transgenic mice expressing human wild-type tau. Brain Struct Funct 214:161–179

    Article  PubMed  Google Scholar 

  29. Liu L, Drouet V, Wu JW, Witter MP, Small SA, Clelland C, Duff K (2012) Trans-synaptic spread of tau pathology in vivo. PLoS One 7:e31302

    Article  PubMed  CAS  Google Scholar 

  30. Goedert M, Clavaguera F, Tolnay M (2010) The propagation of prion-like protein inclusions in neurodegenerative diseases. Trends Neurosci 33:317–325

    Article  PubMed  CAS  Google Scholar 

  31. Francon J, Lennon AM, Fellous A, Mareck A, Pierre M, Nunez J (1982) Heterogeneity of microtubule-associated proteins and brain development. Eur J Biochem 129:465–471

    Article  PubMed  CAS  Google Scholar 

  32. Hong XP, Peng CX, Wei W, Tian Q, Liu YH, Yao XQ, Zhang Y, Cao FY, Wang Q, Wang JZ (2010) Essential role of tau phosphorylation in adult hippocampal neurogenesis. Hippocampus 20:1339–1349

    Article  PubMed  CAS  Google Scholar 

  33. He HJ, Wang XS, Pan R, Wang DL, Liu MN, He RQ (2009) The proline-rich domain of tau plays a role in interactions with actin. BMC Cell Biol 10:81

    Article  PubMed  CAS  Google Scholar 

  34. Chambraud B, Sardin E, Giustiniani J, Dounane O, Schumacher M, Goedert M, Baulieu EE (2010) A role for FKBP52 in tau protein function. Proc Natl Acad Sci U S A 107:2658–2663

    Article  PubMed  CAS  Google Scholar 

  35. Quinta HR, Galigniana MD (2012) The neuroregenerative mechanism mediated by the Hsp90-binding immunophilin FKBP52 resembles the early steps of neuronal differentiation. Br J Pharmacol 166:637–649

    Article  PubMed  CAS  Google Scholar 

  36. Li Y, Chen B (1995) Differential regulation of fyn-associated protein tyrosine kinase activity by macrophage colony-stimulating factor (M-CSF) and granulocyte-macrophage colony-stimulating factor (GM-CSF). J Leukoc Biol 57:484–490

    PubMed  CAS  Google Scholar 

  37. Roberson ED, Halabisky B, Yoo JW, Yao J, Chin J, Yan F, Wu T, Hamto P, Devidze N, Yu GQ, Palop JJ, Noebels JL, Mucke L (2011) Amyloid-beta/Fyn-induced synaptic, network, and cognitive impairments depend on tau levels in multiple mouse models of Alzheimer’s disease. J Neurosci 31:700–711

    Article  PubMed  CAS  Google Scholar 

  38. Usardi A, Pooler AM, Seereeram A, Reynolds CH, Derkinderen P, Anderton B, Hanger DP, Noble W, Williamson R (2011) Tyrosine phosphorylation of tau regulates its interactions with Fyn SH2 domains, but not SH3 domains, altering the cellular localization of tau. FEBS J 278:2927–2937

    Article  PubMed  CAS  Google Scholar 

  39. Zempel H, Mandelkow EM (2012) Linking amyloid-beta and tau: amyloid-beta induced synaptic dysfunction via local wreckage of the neuronal cytoskeleton. Neurodegener Dis 10:64–72

    Article  PubMed  CAS  Google Scholar 

  40. Ballatore C, Lee VM, Trojanowski JQ (2007) Tau-mediated neurodegeneration in Alzheimer’s disease and related disorders. Nat Rev Neurosci 8:663–672

    Article  PubMed  CAS  Google Scholar 

  41. Grundke-Iqbal I, Iqbal K, Quinlan M, Tung YC, Zaidi MS, Wisniewski HM (1986) Microtubule-associated protein tau. A component of Alzheimer paired helical filaments. J Biol Chem 261:6084–6089

    PubMed  CAS  Google Scholar 

  42. Delacourte A, Defossez A (1986) Alzheimer’s disease: tau proteins, the promoting factors of microtubule assembly, are major components of paired helical filaments. J Neurol Sci 76:173–186

    Article  PubMed  CAS  Google Scholar 

  43. Wood JG, Mirra SS, Pollock NJ, Binder LI (1986) Neurofibrillary tangles of Alzheimer disease share antigenic determinants with the axonal microtubule-associated protein tau (tau). Proc Natl Acad Sci U S A 83:4040–4043

    Article  PubMed  CAS  Google Scholar 

  44. Kosik KS, Joachim CL, Selkoe DJ (1986) Microtubule-associated protein tau (tau) is a major antigenic component of paired helical filaments in Alzheimer disease. Proc Natl Acad Sci U S A 83:4044–4048

    Article  PubMed  CAS  Google Scholar 

  45. Nukina N, Ihara Y (1986) One of the antigenic determinants of paired helical filaments is related to tau protein. J Biochem (Tokyo) 99:1541–1544

    Google Scholar 

  46. Goedert M, Wischik CM, Crowther RA, Walker JE, Klug A (1988) Cloning and sequencing of the cDNA encoding a core protein of the paired helical filament of Alzheimer disease: identification as the microtubule-associated protein tau. Proc Natl Acad Sci U S A 85:4051–4055

    Article  PubMed  CAS  Google Scholar 

  47. Wischik CM, Novak M, Thøgersen HC, Edwards PC, Runswick MJ, Jakes R, Walker JE, Milstein C, Roth M, Klug A (1988) Isolation of a fragment of tau derived from the core of the paired helical filament of Alzheimer disease. Proc Natl Acad Sci U S A 85:4506–4510

    Article  PubMed  CAS  Google Scholar 

  48. Kidd M (1963) Paired helical filaments in electron microscopy of Alzheimer’s disease. Nature 197:192–193

    Article  PubMed  CAS  Google Scholar 

  49. Kidd M (1964) Alzheimer’s disease – an electron microscopical study. Brain 87:307–320

    Article  PubMed  CAS  Google Scholar 

  50. Wisniewski HM, Narang HK, Terry RD (1976) Neurofibrillary tangles of paired helical filaments. J Neurol Sci 27:173–181

    Article  PubMed  CAS  Google Scholar 

  51. Crowther RA, Wischik CM (1985) Image reconstruction of the Alzheimer paired helical filament. EMBO J 4:3661–3665

    PubMed  CAS  Google Scholar 

  52. Gozes I, Schmitt H, Littauer UZ (1975) Translation in vitro of rat brain messenger RNA coding for tubulin and actin. Proc Natl Acad Sci U S A 72:701–705

    Article  PubMed  CAS  Google Scholar 

  53. Robert M, Mathuranath PS (2007) Tau and tauopathies. Neurol India 55:11–16

    Article  PubMed  CAS  Google Scholar 

  54. Mason JL, Suzuki K, Chaplin DD, Matsushima GK (2001) Interleukin-1beta promotes repair of the CNS. J Neurosci 21:7046–7052

    PubMed  CAS  Google Scholar 

  55. Temporin K, Tanaka H, Kuroda Y, Okada K, Yachi K, Moritomo H, Murase T, Yoshikawa H (2008) IL-1beta promotes neurite outgrowth by deactivating RhoA via p38 MAPK pathway. Biochem Biophys Res Commun 365:375–380

    Article  PubMed  CAS  Google Scholar 

  56. Arnett HA, Mason J, Marino M, Suzuki K, Matsushima GK, Ting JP (2001) TNF alpha promotes proliferation of oligodendrocyte progenitors and remyelination. Nat Neurosci 4:1116–1122

    Article  PubMed  CAS  Google Scholar 

  57. Platel JC, Dave KA, Gordon V, Lacar B, Rubio ME, Bordey A (2010) NMDA receptors activated by subventricular zone astrocytic glutamate are critical for neuroblast survival prior to entering a synaptic network. Neuron 65:859–872

    Article  PubMed  CAS  Google Scholar 

  58. Grundke-Iqbal I, Iqbal K, Tung YC, Quinlan M, Wisniewski HM, Binder LI (1986) Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. Proc Natl Acad Sci U S A 83:4913–4917

    Article  PubMed  CAS  Google Scholar 

  59. Ihara Y, Nukina N, Miura R, Ogawara M (1986) Phosphorylated tau protein is integrated into paired helical filaments in Alzheimer’s disease. J Biochem (Tokyo) 99:1807–1810

    Google Scholar 

  60. Trojanowski JQ, Lee VM (1995) Phosphorylation of paired helical filament tau in Alzheimer’s disease neurofibrillary lesions: focusing on phosphatases. FASEB J 9:1570–1576

    PubMed  CAS  Google Scholar 

  61. Liu F, Iqbal K, Grundke-Iqbal I, Hart GW, Gong CX (2004) O-GlcNAcylation regulates phosphorylation of tau: a mechanism involved in Alzheimer’s disease. Proc Natl Acad Sci U S A 101:10804–10809

    Article  PubMed  CAS  Google Scholar 

  62. Lee G, Thangavel R, Sharma VM, Litersky JM, Bhaskar K, Fang SM, Do LH, Andreadis A, Van Hoesen G, Ksiezak-Reding H (2004) Phosphorylation of tau by fyn: implications for Alzheimer’s disease. J Neurosci 24:2304–2312

    Article  PubMed  CAS  Google Scholar 

  63. Gong CX, Liu F, Grundke-Iqbal I, Iqbal K (2005) Post-translational modifications of tau protein in Alzheimer’s disease. J Neural Transm 112:813–838

    Article  PubMed  CAS  Google Scholar 

  64. Gordon-Krajcer W, Yang L, Ksiezak-Reding H (2000) Conformation of paired helical filaments blocks dephosphorylation of epitopes shared with fetal tau except Ser199/202 and Ser202/Thr205. Brain Res 856:163–175

    Article  PubMed  CAS  Google Scholar 

  65. Hernandez F, Lucas JJ, Cuadros R, Avila J (2003) GSK-3 dependent phosphoepitopes recognized by PHF-1 and AT-8 antibodies are present in different tau isoforms. Neurobiol Aging 24:1087–1094

    Article  PubMed  CAS  Google Scholar 

  66. Terwel D, Dewachter I, Van Leuven F (2002) Axonal transport, tau protein, and neurodegeneration in Alzheimer’s disease. Neuromolecular Med 2:151–165

    Article  PubMed  CAS  Google Scholar 

  67. Drechsel DN, Hyman AA, Cobb MH, Kirschner MW (1992) Modulation of the dynamic instability of tubulin assembly by the microtubule-associated protein tau. Mol Biol Cell 3:1141–1154

    PubMed  CAS  Google Scholar 

  68. Bramblett GT, Goedert M, Jakes R, Merrick SE, Trojanowski JQ, Lee VM (1993) Abnormal tau phosphorylation at Ser396 in Alzheimer’s disease recapitulates development and contributes to reduced microtubule binding. Neuron 10:1089–1099

    Article  PubMed  CAS  Google Scholar 

  69. Yoshida H, Ihara Y (1993) Tau in paired helical filaments is functionally distinct from fetal tau: assembly incompetence of paired helical filament-tau. J Neurochem 61:1183–1186

    Article  PubMed  CAS  Google Scholar 

  70. Biernat J, Gustke N, Drewes G, Mandelkow EM, Mandelkow E (1993) Phosphorylation of Ser262 strongly reduces binding of tau to microtubules: distinction between PHF-like immunoreactivity and microtubule binding. Neuron 11:153–163

    Article  PubMed  CAS  Google Scholar 

  71. Jameson L, Frey T, Zeeberg B, Dalldorf F, Caplow M (1980) Inhibition of microtubule assembly by phosphorylation of microtubule-associated proteins. Biochemistry 19:2472–2479

    Article  PubMed  CAS  Google Scholar 

  72. Lindwall G, Cole RD (1984) Phosphorylation affects the ability of tau protein to promote microtubule assembly. J Biol Chem 259:5301–5305

    PubMed  CAS  Google Scholar 

  73. Alonso A, Zaidi T, Novak M, Grundke-Iqbal I, Iqbal K (2001) Hyperphosphorylation induces self-assembly of tau into tangles of paired helical filaments/straight filaments. Proc Natl Acad Sci U S A 98:6923–6928

    Article  PubMed  CAS  Google Scholar 

  74. Haase C, Stieler JT, Arendt T, Holzer M (2004) Pseudophosphorylation of tau protein alters its ability for self-aggregation. J Neurochem 88:1509–1520

    Article  PubMed  CAS  Google Scholar 

  75. Litersky JM, Johnson GV (1992) Phosphorylation by cAMP-dependent protein kinase inhibits the degradation of tau by calpain. J Biol Chem 267:1563–1568

    PubMed  CAS  Google Scholar 

  76. Eriksson PS, Perfilieva E, Björk-Eriksson T, Alborn AM, Nordborg C, Peterson DA, Gage FH (1998) Neurogenesis in the adult human hippocampus. Nat Med 4:1313–1317

    Article  PubMed  CAS  Google Scholar 

  77. Drewes G, Ebneth A, Preuss U, Mandelkow EM, Mandelkow E (1997) MARK, a novel family of protein kinases that phosphorylate microtubule-associated proteins and trigger microtubule disruption. Cell 89:297–308

    Article  PubMed  CAS  Google Scholar 

  78. Timm T, von Kries JP, Li X, Zempel H, Mandelkow E, Mandelkow EM (2011) Microtubule affinity regulating kinase activity in living neurons was examined by a genetically encoded fluorescence resonance energy transfer/fluorescence lifetime imaging-based biosensor: inhibitors with therapeutic potential. J Biol Chem 286:41711–41722

    Article  PubMed  CAS  Google Scholar 

  79. Liao X, Zhang Y, Wang Y, Wang J (2004) The effect of cdk-5 overexpression on tau phosphorylation and spatial memory of rat. Sci China C Life Sci 47:251–257

    PubMed  CAS  Google Scholar 

  80. Ziv Y, Ron N, Butovsky O, Landa G, Sudai E, Greenberg N, Cohen H, Kipnis J, Schwartz M (2006) Immune cells contribute to the maintenance of neurogenesis and spatial learning abilities in adulthood. Nat Neurosci 9:268–275

    Article  PubMed  CAS  Google Scholar 

  81. Ohtaki H, Ylostalo JH, Foraker JE, Robinson AP, Reger RL, Shioda S, Prockop DJ (2008) Stem/progenitor cells from bone marrow decrease neuronal death in global ischemia by modulation of inflammatory/immune responses. Proc Natl Acad Sci U S A 105:14638–14643

    Article  PubMed  CAS  Google Scholar 

  82. Baker M, Litvan I, Houlden H, Adamson J, Dickson D, Perez-Tur J, Hardy J, Lynch T, Bigio E, Hutton M (1999) Association of an extended haplotype in the tau gene with progressive supranuclear palsy. Hum Mol Genet 8:711–715

    Article  PubMed  CAS  Google Scholar 

  83. Pittman AM, Myers AJ, Duckworth J, Bryden L, Hanson M, Abou-Sleiman P, Wood NW, Hardy J, Lees A, de Silva R (2004) The structure of the tau haplotype in controls and in progressive supranuclear palsy. Hum Mol Genet 13:1267–1274

    Article  PubMed  CAS  Google Scholar 

  84. Caffrey TM, Wade-Martins R (2007) Functional MAPT haplotypes: bridging the gap between genotype and neuropathology. Neurobiol Dis 27:1–10

    Article  PubMed  CAS  Google Scholar 

  85. Pittman AM, Myers AJ, Abou-Sleiman P, Fung HC, Kaleem M, Marlowe L, Duckworth J, Leung D, Williams D, Kilford L, Thomas N, Morris CM, Dickson D, Wood NW, Hardy J, Lees AJ, de Silva R (2005) Linkage disequilibrium fine mapping and haplotype association analysis of the tau gene in progressive supranuclear palsy and corticobasal degeneration. J Med Genet 42:837–846

    Article  PubMed  CAS  Google Scholar 

  86. Di Maria E, Cammarata S, Parodi MI, Borghi R, Benussi L, Galli M, Galimberti D, Ghidoni R, Gonella D, Novello C, Pollero V, Perroni L, Odetti P, Scarpini E, Binetti G, Tabaton M (2010) The h1 haplotype of the tau gene (mapt) is associated with mild cognitive impairment. J Alzheimers Dis 19:909–914

    PubMed  CAS  Google Scholar 

  87. Borroni B, Grassi M, Agosti C, Premi E, Archetti S, Alberici A, Bellelli G, Caimi L, Di Luca M, Padovani A (2010) Establishing short-term prognosis in frontotemporal lobar degeneration spectrum: Role of genetic background and clinical phenotype. Neurobiol Aging 31:270–279

    Article  PubMed  Google Scholar 

  88. Desai AK, Chand P (2009) Tau-based therapies for Alzheimer’s disease: wave of the future? Prim Psychiatry 16:40–46

    Google Scholar 

  89. Hauw JJ, Daniel SE, Dickson D, Horoupian DS, Jellinger K, Lantos PL, McKee A, Tabaton M, Litvan I (1994) Preliminary NINDS neuropathologic criteria for Steele-Richardson-Olszewski syndrome (progressive supranuclear palsy). Neurology 44:2015–2019

    Article  PubMed  CAS  Google Scholar 

  90. Dickson DW, Rademakers R, Hutton ML (2007) Progressive supranuclear palsy: pathology and genetics. Brain Pathol 17:74–82

    Article  PubMed  CAS  Google Scholar 

  91. Spillantini MG, Bird TD, Ghetti B (1998) Frontotemporal dementia and Parkinsonism linked to chromosome 17: a new group of tauopathies. Brain Pathol 8:387–402

    Article  PubMed  CAS  Google Scholar 

  92. Litvan I, Agid Y, Jankovic J, Goetz C, Brandel JP, Lai EC, Wenning G, D'Olhaberriague L, Verny M, Chaudhuri KR, McKee A, Jellinger K, Bartko JJ, Mangone CA, Pearce RK (1996) Accuracy of clinical criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome). Neurology 46:922–930

    Article  PubMed  CAS  Google Scholar 

  93. Pillon B, Dubois B, Ploska A, Agid Y (1991) Severity and specificity of cognitive impairment in Alzheimer’s, Huntington’s, and Parkinson’s diseases and progressive supranuclear palsy. Neurology 41:634–643

    Article  PubMed  CAS  Google Scholar 

  94. Litvan I, Agid Y, Calne D, Campbell G, Dubois B, Duvoisin RC, Goetz CG, Golbe LI, Grafman J, Growdon JH, Hallett M, Jankovic J, Quinn NP, Tolosa E, Zee DS (1996) Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop. Neurology 47:1–9

    Article  PubMed  CAS  Google Scholar 

  95. Schrag A, Ben-Shlomo Y, Quinn NP (1999) Prevalence of progressive supranuclear palsy and multiple system atrophy: a cross-sectional study. Lancet 354:1771–1775

    Article  PubMed  CAS  Google Scholar 

  96. Testa D, Monza D, Ferrarini M, Soliveri P, Girotti F, Filippini G (2001) Comparison of natural histories of progressive supranuclear palsy and multiple system atrophy. Neurol Sci 22:247–251

    Article  PubMed  CAS  Google Scholar 

  97. Golbe LI, Ohman-Strickland PA (2007) A clinical rating scale for progressive supranuclear palsy. Brain 130:1552–1565

    Article  PubMed  Google Scholar 

  98. Paviour DC, Price SL, Lees AJ, Fox NC (2007) MRI derived brain atrophy in PSP and MSA-P. Determining sample size to detect treatment effects. J Neurol 254:478–481

    Article  PubMed  Google Scholar 

  99. Whitwell JL, Jack CR Jr, Parisi JE, Knopman DS, Boeve BF, Petersen RC, Ferman TJ, Dickson DW, Josephs KA (2007) Rates of cerebral atrophy differ in different degenerative pathologies. Brain 130:1148–1158

    Article  PubMed  Google Scholar 

  100. Cordato NJ, Duggins AJ, Halliday GM, Morris JG, Pantelis C (2005) Clinical deficits correlate with regional cerebral atrophy in progressive supranuclear palsy. Brain 128:1259–1266

    Article  PubMed  CAS  Google Scholar 

  101. Boxer AL, Geschwind MD, Belfor N, Gorno-Tempini ML, Schauer GF, Miller BL, Weiner MW, Rosen HJ (2006) Patterns of brain atrophy that differentiate corticobasal degeneration syndrome from progressive supranuclear palsy. Arch Neurol 63:81–86

    Article  PubMed  Google Scholar 

  102. Hutton M, Lendon CL, Rizzu P, Baker M, Froelich S, Houlden H, Pickering-Brown S, Chakraverty S, Isaacs A, Grover A, Hackett J, Adamson J, Lincoln S, Dickson D, Davies P, Petersen RC, Stevens M, de Graaff E, Wauters E, van Baren J, Hillebrand M, Joosse M, Kwon JM, Nowotny P, Che LK, Norton J, Morris JC, Reed LA, Trojanowski J, Basun H, Lannfelt L, Neystat M, Fahn S, Dark F, Tannenberg T, Dodd PR, Hayward N, Kwok JB, Schofield PR, Andreadis A, Snowden J, Craufurd D, Neary D, Owen F, Oostra BA, Hardy J, Goate A, van Swieten J, Mann D, Lynch T, Heutink P (1998) Association of missense and 5'-splice-site mutations in tau with the inherited dementia FTDP-17. Nature 393:702–705

    Article  PubMed  CAS  Google Scholar 

  103. Rademakers R, Neumann M, Mackenzie IR (2012) Advances in understanding the molecular basis of frontotemporal dementia. Nat Rev Neurol 8:423–434

    PubMed  CAS  Google Scholar 

  104. Guillozet-Bongaarts AL, Glajch KE, Libson EG, Cahill ME, Bigio E, Berry RW, Binder LI (2007) Phosphorylation and cleavage of tau in non-AD tauopathies. Acta Neuropathol 113:513–520

    Article  PubMed  CAS  Google Scholar 

  105. Lee RH, Pulin AA, Seo MJ, Kota DJ, Ylostalo J, Larson BL, Semprun-Prieto L, Delafontaine P, Prockop DJ (2009) Intravenous hMSCs improve myocardial infarction in mice because cells embolized in lung are activated to secrete the anti-inflammatory protein TSG-6. Cell Stem Cell 5:54–63

    Article  PubMed  CAS  Google Scholar 

  106. Nemeth K, Leelahavanichkul A, Yuen PS, Mayer B, Parmelee A, Doi K, Robey PG, Leelahavanichkul K, Koller BH, Brown JM, Hu X, Jelinek I, Star RA, Mezey E (2009) Bone marrow stromal cells attenuate sepsis via prostaglandin E(2)-dependent reprogramming of host macrophages to increase their interleukin-10 production. Nat Med 15:42–49

    Article  PubMed  CAS  Google Scholar 

  107. Ginsberg SD, Che S, Counts SE, Mufson EJ (2006) Shift in the ratio of three-repeat tau and four-repeat tau mRNAs in individual cholinergic basal forebrain neurons in mild cognitive impairment and Alzheimer’s disease. J Neurochem 96:1401–1408

    Article  PubMed  CAS  Google Scholar 

  108. Schrepfer S, Deuse T, Reichenspurner H, Fischbein MP, Robbins RC, Pelletier MP (2007) Stem cell transplantation: the lung barrier. Transplant Proc 39:573–576

    Article  PubMed  CAS  Google Scholar 

  109. Shaw LM, Vanderstichele H, Knapik-Czajka M, Clark CM, Aisen PS, Petersen RC, Blennow K, Soares H, Simon A, Lewczuk P, Dean R, Siemers E, Potter W, Lee VM, Trojanowski JQ, Alzheimer’s Disease Neuroimaging Initiative (2009) Cerebrospinal fluid biomarker signature in Alzheimer’s disease neuroimaging initiative subjects. Ann Neurol 65:403–413

    Article  PubMed  CAS  Google Scholar 

  110. Buerger K, Frisoni G, Uspenskaya O, Ewers M, Zetterberg H, Geroldi C, Binetti G, Johannsen P, Rossini PM, Wahlund LO, Vellas B, Blennow K, Hampel H (2009) Validation of Alzheimer’s disease CSF and plasma biological markers: the multicentre reliability study of the pilot European Alzheimer’s Disease Neuroimaging Initiative (E-ADNI). Exp Gerontol 44:579–585

    Article  PubMed  CAS  Google Scholar 

  111. Rissman RA et al (2004) Caspase-cleavage of tau is an early event in Alzheimer disease tangle pathology. J Clin Invest 114:121–130

    PubMed  CAS  Google Scholar 

  112. Ohtaki H, Satoh A, Nakamachi T, Yofu S, Dohi K, Mori H, Ohara K, Miyamoto K, Hashimoto H, Shintani N, Baba A, Matsunaga M, Shioda S (2010) Regulation of oxidative stress by pituitary adenylate cyclase-activating polypeptide (PACAP) mediated by PACAP receptor. J Mol Neurosci 42:397–403

    Article  PubMed  CAS  Google Scholar 

  113. Mori H, Nakamachi T, Ohtaki H, Yofu S, Sato A, Endo K, Iso Y, Suzuki H, Takeyama Y, Shintani N, Hashimoto H, Baba A, Shioda S (2010) Cardioprotective effect of endogenous pituitary adenylate cyclase-activating polypeptide on doxorubicin-induced cardiomyopathy in mice. Circ J 74:1183–1190

    Article  PubMed  CAS  Google Scholar 

  114. Stomrud E, Hansson O, Zetterberg H, Blennow K, Minthon L, Londos E (2010) Correlation of longitudinal cerebrospinal fluid biomarkers with cognitive decline in healthy older adults. Arch Neurol 67:217–223

    Article  PubMed  Google Scholar 

  115. Shiryaev N, Jouroukhin Y, Gozes I (2010) 3R tau expression modifies behavior in transgenic mice. J Neurosci Res 88:2727–2735

    PubMed  CAS  Google Scholar 

  116. Borroni B, Hansson O, Zetterberg H, Blennow K, Minthon L, Londos E, Gardoni F, Parnetti L, Magno L, Malinverno M, Saggese E, Calabresi P, Spillantini MG, Padovani A, Di Luca M (2009) Pattern of Tau forms in CSF is altered in progressive supranuclear palsy. Neurobiol Aging 30:34–40

    Article  PubMed  CAS  Google Scholar 

  117. Kuiperij HB, Verbeek MM (2012) Detection of tau forms in CSF requires sensitive techniques. Neurobiol Aging 33:1841

    Article  CAS  Google Scholar 

  118. Constantinescu R, Zetterberg H, Holmberg B, Rosengren L (2009) Levels of brain related proteins in cerebrospinal fluid: an aid in the differential diagnosis of parkinsonian disorders. Parkinsonism Relat Disord 15:205–212

    Article  PubMed  Google Scholar 

  119. Ewers M, Walsh C, Trojanowski JQ, Shaw LM, Petersen RC, Jack CR Jr, Feldman HH, Bokde AL, Alexander GE, Scheltens P, Vellas B, Dubois B, Weiner M, Hampel H, North American Alzheimer’s Disease Neuroimaging Initiative (ADNI) (2012) Prediction of conversion from mild cognitive impairment to Alzheimer’s disease dementia based upon biomarkers and neuropsychological test performance. Neurobiol Aging 33:1203–1214, e1202

    Article  PubMed  CAS  Google Scholar 

  120. Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, Iwatsubo T, Jack CR Jr, Kaye J, Montine TJ, Park DC, Reiman EM, Rowe CC, Siemers E, Stern Y, Yaffe K, Carrillo MC, Thies B, Morrison-Bogorad M, Wagster MV, Phelps CH (2011) Toward defining the preclinical stages of Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 7:280–292

    Article  PubMed  Google Scholar 

  121. Ray S, Britschgi M, Herbert C, Takeda-Uchimura Y, Boxer A, Blennow K, Friedman LF, Galasko DR, Jutel M, Karydas A, Kaye JA, Leszek J, Miller BL, Minthon L, Quinn JF, Rabinovici GD, Robinson WH, Sabbagh MN, So YT, Sparks DL, Tabaton M, Tinklenberg J, Yesavage JA, Tibshirani R, Wyss-Coray T (2007) Classification and prediction of clinical Alzheimer’s diagnosis based on plasma signaling proteins. Nat Med 13:1359–1362

    Article  PubMed  CAS  Google Scholar 

  122. Ewers M, Mielke MM, Hampel H (2010) Blood-based biomarkers of microvascular pathology in Alzheimer’s disease. Exp Gerontol 45:75–79

    Article  PubMed  CAS  Google Scholar 

  123. Rye PD, Booij BB, Grave G, Lindahl T, Kristiansen L, Andersen HM, Horndalsveen PO, Nygaard HA, Naik M, Hoprekstad D, Wetterberg P, Nilsson C, Aarsland D, Sharma P, Lönneborg A (2011) A novel blood test for the early detection of Alzheimer’s disease. J Alzheimers Dis 23:121–129

    PubMed  CAS  Google Scholar 

  124. Booij BB, Lindahl T, Wetterberg P, Skaane NV, Sæbø S, Feten G, Rye PD, Kristiansen LI, Hagen N, Jensen M, Bårdsen K, Winblad B, Sharma P, Lönneborg A (2011) A gene expression pattern in blood for the early detection of Alzheimer’s disease. J Alzheimers Dis 23:109–119

    PubMed  CAS  Google Scholar 

  125. Weigand SD, Vemuri P, Wiste HJ, Senjem ML, Pankratz VS, Aisen PS, Weiner MW, Petersen RC, Shaw LM, Trojanowski JQ, Knopman DS, Jack CR Jr, Alzheimer’s Disease Neuroimaging Initiative (2011) Transforming cerebrospinal fluid Abeta42 measures into calculated Pittsburgh Compound B units of brain Abeta amyloid. Alzheimers Dement 7:133–141

    Article  PubMed  CAS  Google Scholar 

  126. Braskie MN, Klunder AD, Hayashi KM, Protas H, Kepe V, Miller KJ, Huang SC, Barrio JR, Ercoli LM, Siddarth P, Satyamurthy N, Liu J, Toga AW, Bookheimer SY, Small GW, Thompson PM (2010) Plaque and tangle imaging and cognition in normal aging and Alzheimer’s disease. Neurobiol Aging 31:1669–1678

    Article  PubMed  Google Scholar 

  127. Fodero-Tavoletti MT, Okamura N, Furumoto S, Mulligan RS, Connor AR, McLean CA, Cao D, Rigopoulos A, Cartwright GA, O'Keefe G, Gong S, Adlard PA, Barnham KJ, Rowe CC, Masters CL, Kudo Y, Cappai R, Yanai K, Villemagne VL (2011) 18F-THK523: a novel in vivo tau imaging ligand for Alzheimer’s disease. Brain 134:1089–1100

    Article  PubMed  Google Scholar 

  128. Arriagada PV, Growdon JH, Hedley-Whyte ET, Hyman BT (1992) Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer’s disease. Neurology 42:631–639

    Article  PubMed  CAS  Google Scholar 

  129. Braak H, Braak E (1998) Evolution of neuronal changes in the course of Alzheimer’s disease. J Neural Transm Suppl 53:127–140

    Article  PubMed  CAS  Google Scholar 

  130. Desikan RS, McEvoy LK, Thompson WK, Holland D, Brewer JB, Aisen PS, Sperling RA, Dale AM, Alzheimer’s Disease Neuroimaging Initiative (2012) Amyloid-beta-associated clinical decline occurs only in the presence of elevated P-tau. Arch Neurol 69:709–713

    PubMed  Google Scholar 

  131. Gozes I (2002) Tau as a drug target in Alzheimer’s disease. J Mol Neurosci 19:337–338

    Article  PubMed  CAS  Google Scholar 

  132. Bulic B, Pickhardt M, Schmidt B, Mandelkow EM, Waldmann H, Mandelkow E (2009) Development of tau aggregation inhibitors for Alzheimer’s disease. Angew Chem Int Ed Engl 48:1740–1752

    Article  PubMed  CAS  Google Scholar 

  133. Stewart AJ, Fox A, Morimoto BH, Gozes I (2007) Looking for novel ways to treat the hallmarks of Alzheimer’s disease. Expert Opin Investig Drugs 16:1183–1196

    Article  PubMed  CAS  Google Scholar 

  134. Lemere CA, Masliah E (2010) Can Alzheimer disease be prevented by amyloid-beta immunotherapy? Nat Rev Neurol 6:108–119

    Article  PubMed  CAS  Google Scholar 

  135. Winblad B, Andreasen N, Minthon L, Floesser A, Imbert G, Dumortier T, Maguire RP, Blennow K, Lundmark J, Staufenbiel M, Orgogozo JM, Graf A (2012) Safety, tolerability, and antibody response of active Abeta immunotherapy with CAD106 in patients with Alzheimer’s disease: randomised, double-blind, placebo-controlled, first-in-human study. Lancet Neurol 11:597–604

    Article  PubMed  CAS  Google Scholar 

  136. Voss K, Combs B, Patterson KR, Binder LI, Gamblin TC (2012) Hsp70 alters tau function and aggregation in an isoform specific manner. Biochemistry 51:888–898

    Article  PubMed  CAS  Google Scholar 

  137. Yu W, Polepalli J, Wagh D, Rajadas J, Malenka R, Lu B (2012) A critical role for the PAR-1/MARK-tau axis in mediating the toxic effects of Abeta on synapses and dendritic spines. Hum Mol Genet 21:1384–1390

    Article  PubMed  CAS  Google Scholar 

  138. Gotz J, Ittner A, Ittner LM (2012) Tau-targeted treatment strategies in Alzheimer’s disease. Br J Pharmacol 165:1246–1259

    Article  PubMed  CAS  Google Scholar 

  139. Mondragon-Rodriguez S, Perry G, Zhu X, Boehm J (2012) Amyloid Beta and tau proteins as therapeutic targets for Alzheimer’s disease treatment: rethinking the current strategy. Int J Alzheimers Dis 2012:630182

    PubMed  Google Scholar 

  140. Hernandez F, Lucas JJ, Avila J (2013) GSK3 and Tau: two convergence points in Alzheimer’s disease. J Alzheimers Dis 33:S141–144

    Google Scholar 

  141. Schaeffer V, Lavenir I, Ozcelik S, Tolnay M, Winkler DT, Goedert M (2012) Stimulation of autophagy reduces neurodegeneration in a mouse model of human tauopathy. Brain 135(Pt 7):2169–2177

    Article  PubMed  Google Scholar 

  142. Morris M, Maeda S, Vossel K, Mucke L (2011) The many faces of tau. Neuron 70:410–426

    Article  PubMed  CAS  Google Scholar 

  143. Brunden KR, Trojanowski JQ, Lee VM (2009) Advances in tau-focused drug discovery for Alzheimer’s disease and related tauopathies. Nat Rev Drug Discov 8:783–793

    Article  PubMed  CAS  Google Scholar 

  144. Paquet D, Bhat R, Sydow A, Mandelkow EM, Berg S, Hellberg S, Fälting J, Distel M, Köster RW, Schmid B, Haass C (2009) A zebrafish model of tauopathy allows in vivo imaging of neuronal cell death and drug evaluation. J Clin Invest 119:1382–1395

    Article  PubMed  CAS  Google Scholar 

  145. Chatterjee S, Sang TK, Lawless GM, Jackson GR (2009) Dissociation of tau toxicity and phosphorylation: role of GSK-3beta, MARK and Cdk5 in a Drosophila model. Hum Mol Genet 18:164–177

    Article  PubMed  CAS  Google Scholar 

  146. Mudher A, Shepherd D, Newman TA, Mildren P, Jukes JP, Squire A, Mears A, Drummond JA, Berg S, MacKay D, Asuni AA, Bhat R, Lovestone S (2004) GSK-3beta inhibition reverses axonal transport defects and behavioural phenotypes in Drosophila. Mol Psychiatry 9:522–530

    Article  PubMed  CAS  Google Scholar 

  147. Gotz J, Ittner LM (2008) Animal models of Alzheimer’s disease and frontotemporal dementia. Nat Rev Neurosci 9:532–544

    Article  PubMed  CAS  Google Scholar 

  148. Ramsden M, Kotilinek L, Forster C, Paulson J, McGowan E, SantaCruz K, Guimaraes A, Yue M, Lewis J, Carlson G, Hutton M, Ashe KH (2005) Age-dependent neurofibrillary tangle formation, neuron loss, and memory impairment in a mouse model of human tauopathy (P301L). J Neurosci 25:10637–10647

    Article  PubMed  CAS  Google Scholar 

  149. Le Blanc K, Ringden O (2006) Mesenchymal stem cells: properties and role in clinical bone marrow transplantation. Curr Opin Immunol 18:586–591

    Article  PubMed  CAS  Google Scholar 

  150. Prockop DJ, Olson SD (2007) Clinical trials with adult stem/progenitor cells for tissue repair: let’s not overlook some essential precautions. Blood 109:3147–3151

    Article  PubMed  CAS  Google Scholar 

  151. Giordano A, Galderisi U, Marino IR (2007) From the laboratory bench to the patient’s bedside: an update on clinical trials with mesenchymal stem cells. J Cell Physiol 211:27–35

    Article  PubMed  CAS  Google Scholar 

  152. Caplan AI (2007) Adult mesenchymal stem cells for tissue engineering versus regenerative medicine. J Cell Physiol 213:341–347

    Article  PubMed  CAS  Google Scholar 

  153. Bassan M, Zamostiano R, Davidson A, Pinhasov A, Giladi E, Perl O, Bassan H, Blat C, Gibney G, Glazner G, Brenneman DE, Gozes I (1999) Complete sequence of a novel protein containing a femtomolar-activity-dependent neuroprotective peptide. J Neurochem 72:1283–1293

    Article  PubMed  CAS  Google Scholar 

  154. Zamostiano R, Pinhasov A, Gelber E, Steingart RA, Seroussi E, Giladi E, Bassan M, Wollman Y, Eyre HJ, Mulley JC, Brenneman DE, Gozes I (2001) Cloning and characterization of the human activity-dependent neuroprotective protein. J Biol Chem 276:708–714

    Article  PubMed  CAS  Google Scholar 

  155. Gozes I (2007) Activity-dependent neuroprotective protein: from gene to drug candidate. Pharmacol Ther 114:146–154

    Article  PubMed  CAS  Google Scholar 

  156. Idan-Feldman A, Ostritsky R, Gozes I (2012) Tau and caspase 3 as targets for neuroprotection. Int J Alzheimers Dis 2012:493670

    PubMed  Google Scholar 

  157. Divinski I, Holtser-Cochav M, Vulih-Schultzman I, Steingart RA, Gozes I (2006) Peptide neuroprotection through specific interaction with brain tubulin. J Neurochem 98:973–984

    Article  PubMed  CAS  Google Scholar 

  158. Divinski I, Mittelman L, Gozes I (2004) A femtomolar acting octapeptide interacts with tubulin and protects astrocytes against zinc intoxication. J Biol Chem 279:28531–28538

    Article  PubMed  CAS  Google Scholar 

  159. Gozes I, Divinsky I, Pilzer I, Fridkin M, Brenneman DE, Spier AD (2003) From vasoactive intestinal peptide (VIP) through activity-dependent neuroprotective protein (ADNP) to NAP: a view of neuroprotection and cell division. J Mol Neurosci 20:315–322

    Article  PubMed  CAS  Google Scholar 

  160. Javitt DC, Buchanan RW, Keefe RS, Kern R, McMahon RP, Green MF, Lieberman J, Goff DC, Csernansky JG, McEvoy JP, Jarskog F, Seidman LJ, Gold JM, Kimhy D, Nolan KS, Barch DS, Ball MP, Robinson J, Marder SR (2012) Effect of the neuroprotective peptide davunetide (AL-108) on cognition and functional capacity in schizophrenia. Schizophr Res 136:25–31

    Article  PubMed  Google Scholar 

  161. Gozes I, Stewart A, Morimoto B, Fox A, Sutherland K, Schmeche D (2009) Addressing Alzheimer’s disease tangles: from NAP to AL-108. Curr Alzheimer Res 6:455–460

    Article  PubMed  CAS  Google Scholar 

  162. Butler D, Bendiske J, Michaelis ML, Karanian DA, Bahr BA (2007) Microtubule-stabilizing agent prevents protein accumulation-induced loss of synaptic markers. Eur J Pharmacol 562:20–27

    Article  PubMed  CAS  Google Scholar 

  163. Zhang B, Carroll J, Trojanowski JQ, Yao Y, Iba M, Potuzak JS, Hogan AM, Xie SX, Ballatore C, Smith AB 3rd, Lee VM, Brunden KR (2012) The microtubule-stabilizing agent, epothilone D, reduces axonal dysfunction, neurotoxicity, cognitive deficits, and Alzheimer-like pathology in an interventional study with aged tau transgenic mice. J Neurosci 32:3601–3611

    Article  PubMed  CAS  Google Scholar 

  164. Wischik CM, Edwards PC, Lai RY, Roth M, Harrington CR (1996) Selective inhibition of Alzheimer disease-like tau aggregation by phenothiazines. Proc Natl Acad Sci U S A 93:11213–11218

    Article  PubMed  CAS  Google Scholar 

  165. Martinez A, Perez DI (2008) GSK-3 inhibitors: a ray of hope for the treatment of Alzheimer’s disease? J Alzheimers Dis 15:181–191

    PubMed  CAS  Google Scholar 

  166. Luna-Medina R, Cortes-Canteli M, Sanchez-Galiano S, Morales-Garcia JA, Martinez A, Santos A, Perez-Castillo A (2007) NP031112, a thiadiazolidinone compound, prevents inflammation and neurodegeneration under excitotoxic conditions: potential therapeutic role in brain disorders. J Neurosci 27:5766–5776

    Article  PubMed  CAS  Google Scholar 

  167. Pickhardt M, Larbig G, Khlistunova I, Coksezen A, Meyer B, Mandelkow EM, Schmidt B, Mandelkow E (2007) Phenylthiazolyl-hydrazide and its derivatives are potent inhibitors of tau aggregation and toxicity in vitro and in cells. Biochemistry 46:10016–10023

    Article  PubMed  CAS  Google Scholar 

  168. Crowe A, Huang W, Ballatore C, Johnson RL, Hogan AM, Huang R, Wichterman J, McCoy J, Huryn D, Auld DS, Smith AB 3rd, Inglese J, Trojanowski JQ, Austin CP, Brunden KR, Lee VM (2009) Identification of aminothienopyridazine inhibitors of tau assembly by quantitative high-throughput screening. Biochemistry 48:7732–7745

    Article  PubMed  CAS  Google Scholar 

  169. Wang Y, Martinez-Vicente M, Krüger U, Kaushik S, Wong E, Mandelkow EM, Cuervo AM, Mandelkow E (2009) Tau fragmentation, aggregation and clearance: the dual role of lysosomal processing. Hum Mol Genet 18:4153–4170

    Article  PubMed  CAS  Google Scholar 

  170. Hanger DP, Anderton BH, Noble W (2009) Tau phosphorylation: the therapeutic challenge for neurodegenerative disease. Trends Mol Med 15:112–119

    Article  PubMed  CAS  Google Scholar 

  171. Liu M, Choi S, Cuny GD, Ding K, Dobson BC, Glicksman MA, Auerbach K, Stein RL (2008) Kinetic studies of Cdk5/p25 kinase: phosphorylation of tau and complex inhibition by two prototype inhibitors. Biochemistry 47:8367–8377

    Article  PubMed  CAS  Google Scholar 

  172. Engel T, Goñi-Oliver P, Gómez de Barreda E, Lucas JJ, Hernández F, Avila J (2008) Lithium, a potential protective drug in Alzheimer’s disease. Neurodegener Dis 5:247–249

    Article  PubMed  CAS  Google Scholar 

  173. Eldar-Finkelman H, Eisenstein M (2009) Peptide inhibitors targeting protein kinases. Curr Pharm Des 15:2463–2470

    Article  PubMed  CAS  Google Scholar 

  174. Iqbal K, Grundke-Iqbal I (2008) Alzheimer neurofibrillary degeneration: significance, etiopathogenesis, therapeutics and prevention. J Cell Mol Med 12:38–55

    Article  PubMed  CAS  Google Scholar 

  175. Le Corre S, Klafki HW, Plesnila N, Hübinger G, Obermeier A, Sahagún H, Monse B, Seneci P, Lewis J, Eriksen J, Zehr C, Yue M, McGowan E, Dickson DW, Hutton M, Roder HM (2006) An inhibitor of tau hyperphosphorylation prevents severe motor impairments in tau transgenic mice. Proc Natl Acad Sci U S A 103:9673–9678

    Article  PubMed  CAS  Google Scholar 

  176. Dickey CA, Koren J, Zhang YJ, Xu YF, Jinwal UK, Birnbaum MJ, Monks B, Sun M, Cheng JQ, Patterson C, Bailey RM, Dunmore J, Soresh S, Leon C, Morgan D, Petrucelli L (2008) Akt and CHIP coregulate tau degradation through coordinated interactions. Proc Natl Acad Sci U S A 105:3622–3627

    Article  PubMed  CAS  Google Scholar 

  177. Takeda A, Arai N, Komori T, Iseki E, Kato S, Oda M (1997) Tau immunoreactivity in glial cytoplasmic inclusions in multiple system atrophy. Neurosci Lett 234:63–66

    Article  PubMed  CAS  Google Scholar 

  178. Sigurdsson EM (2009) Tau-focused immunotherapy for Alzheimer’s disease and related tauopathies. Curr Alzheimer Res 6:446–450

    Article  PubMed  CAS  Google Scholar 

  179. Rosenmann H, Meiner Z, Geylis V, Abramsky O, Steinitz M (2006) Detection of circulating antibodies against tau protein in its unphosphorylated and in its neurofibrillary tangles-related phosphorylated state in Alzheimer’s disease and healthy subjects. Neurosci Lett 410:90–93

    Article  PubMed  CAS  Google Scholar 

  180. Lasagna-Reeves CA, Castillo-Carranza DL, Sengupta U, Sarmiento J, Troncoso J, Jackson GR, Kayed R (2012) Identification of oligomers at early stages of tau aggregation in Alzheimer’s disease. FASEB J 26(5):1946–1959

    Article  PubMed  CAS  Google Scholar 

  181. Lasagna-Reeves CA, Castillo-Carranza DL, Jackson GR, Kayed R (2011) Tau oligomers as potential targets for immunotherapy for Alzheimer’s disease and tauopathies. Curr Alzheimer Res 8:659–665

    Article  PubMed  CAS  Google Scholar 

  182. Chai X, Wu S, Murray TK, Kinley R, Cella CV, Sims H, Buckner N, Hanmer J, Davies P, O'Neill MJ, Hutton ML, Citron M (2011) Passive immunization with anti-Tau antibodies in two transgenic models: reduction of Tau pathology and delay of disease progression. J Biol Chem 286:34457–34467

    Article  PubMed  CAS  Google Scholar 

  183. Bi M, Ittner A, Ke YD, Gotz J, Ittner LM (2011) Tau-targeted immunization impedes progression of neurofibrillary histopathology in aged P301L tau transgenic mice. PLoS One 6:e26860

    Article  PubMed  CAS  Google Scholar 

  184. Boutajangout A, Ingadottir J, Davies P, Sigurdsson EM (2011) Passive immunization targeting pathological phospho-tau protein in a mouse model reduces functional decline and clears tau aggregates from the brain. J Neurochem 118:658–667

    Article  PubMed  CAS  Google Scholar 

  185. Boimel M, Grigoriadis N, Lourbopoulos A, Haber E, Abramsky O, Rosenmann H (2010) Efficacy and safety of immunization with phosphorylated tau against neurofibrillary tangles in mice. Exp Neurol 224:472–485

    Article  PubMed  CAS  Google Scholar 

  186. Trojanowski JQ, Duff K, Fillit H, Koroshetz W, Kuret J, Murphy D, Refolo L, Frontotemporal Dementia (FTD) Working Group on FTD Drug Discovery (2008) New directions for frontotemporal dementia drug discovery. Alzheimers Dement 4:89–93

    Article  PubMed  CAS  Google Scholar 

  187. Iqbal K, Chohan MO, Grundke-Iqbal I (2008) Stratification of patients is the way to go to develop neuroprotective/disease-modifying drugs for Alzheimer’s disease. J Alzheimers Dis 15:339–345

    PubMed  CAS  Google Scholar 

Download references

Acknowledgements

I am grateful to the Allon Therapeutics team for valuable input. Studies were supported by Allon Therapeutics Inc.

Author information

Authors and Affiliations

  1. Department of Human Molecular Genetics and Biochemistry, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, 69978, Israel

    Illana Gozes

  2. The Lily and Avraham Gildor Chair for the Investigation of Growth Factors, Tel Aviv University, Tel Aviv, 69978, Israel

    Illana Gozes

  3. The Adams Super Center for Brain Studies and The Edersheim Levie-Gitter fMRI Institute, Tel Aviv University, Tel Aviv, 69978, Israel

    Illana Gozes

  4. The Dr. Diana and Zelman Elton (Elbaum) Laboratory for Molecular Neuroendocrinology, Tel Aviv University, Tel Aviv, 69978, Israel

    Illana Gozes

Authors
  1. Illana Gozes
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Illana Gozes .

Editor information

Editors and Affiliations

  1. , Molecular Pharmacology, Technion, Institute of Technology, Efron, Haifa, 31096, Israel

    Silvia Mandel

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer Science+Business Media Dordrecht

About this chapter

Cite this chapter

Gozes, I. (2013). Tau Pathology: A Selected View on the Current Status. In: Mandel, S. (eds) Neurodegenerative Diseases: Integrative PPPM Approach as the Medicine of the Future. Advances in Predictive, Preventive and Personalised Medicine, vol 2. Springer, Dordrecht. https://doi.org/10.1007/978-94-007-5866-7_5

Download citation

  • DOI: https://doi.org/10.1007/978-94-007-5866-7_5

  • Published:

  • Publisher Name: Springer, Dordrecht

  • Print ISBN: 978-94-007-5865-0

  • Online ISBN: 978-94-007-5866-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation